BioMarin Pharmaceutical has reported positive three-year data from an ongoing Phase I/II trial of its investigational gene therapy valoctocogene roxaparvovec.

Developed to treat adults with severe haemophilia A, the drug has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) and priority medicines (PRIME) access from the European Medicines Agency (EMA).

The therapeutic also received orphan drug designation from both regulators.

According to the study results, bleed rate control with 6e13vg/kg dose of the gene therapy was sustained at three years, with a median annualised bleed rate (ABR) of 0 and a mean ABR of 0.7.

The mean ABR is said to represent a 96% reduction over three years.

Data showed that 71%, 86% and 86% of patients had zero bleeds requiring Factor VIII (FVIII) infusions in the first, second and third years, respectively. This demonstrates an improvement from 14% in the year prior to study enrolment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, a 96% decrease in mean FVIII usage was observed over three years.  In the first, second and third years, the mean FVIII usage reduction was 98%, 94% and 96%, respectively.

BioMarin Pharmaceutical global research and development (R&D) president Hank Fuchs said: “These data confirm that valoctocogene roxaparvovec has the potential to profoundly impact the lives of people with severe haemophilia A through a sustained reduction in bleeds and FVIII usage.

"Statistical modelling anticipates that bleeding control will be maintained for at least eight years after gene transfer."

“More conservative statistical modelling anticipates that bleeding control will be maintained for at least eight years after gene transfer.”

BioMarin CEO Jean-Jacques Bienaime said that the value of valoctocogene roxaparvovec could be $2m based on the cost of five years of the current standard-of-care treatment, reported Reuters.

The company is currently conducting six clinical studies as part of its comprehensive gene therapy programme for severe haemophilia A treatment.